A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Yonsei University
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Louisiana State University Health Sciences Center Shreveport
Fred Hutchinson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Mayo Clinic
University of Arizona
Ohio State University Comprehensive Cancer Center
Yale University
Niguarda Hospital
US Oncology Research
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Boston Medical Center
Hoag Memorial Hospital Presbyterian
Heidelberg University
Ann & Robert H Lurie Children's Hospital of Chicago
East Valley Hematology and Oncology Medical Group